Literature DB >> 7697908

Presentation of cartilage proteoglycan to a T cell hybridoma derived from a mouse with proteoglycan-induced arthritis.

F R Brennan1, G Negroiu, E I Buzás, C Fülöp, K Holló, K Mikecz, T T Glant.   

Abstract

Immunization of BALB/c mice with human fetal cartilage proteoglycan (PG) produces progressive polyarthritis, and T cells play key roles in the development of the disease. To gain an understanding of how PG is presented to autoreactive T cells by synovial antigen-presenting cells (APC), we examined the abilities of various syngeneic APC in presenting PG to a specific T cell hybridoma 5/4E8, derived from a mouse with PG-induced arthritis. A20 B lymphoma cells and spleen cells were strong presenters of PG, but synoviocytes and P388D1 macrophages could only present PG effectively after stimulation with interferon-gamma (IFN-gamma). The IFN-gamma exerted its effect by up-regulating both MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression by these cells as neutralizing antibodies to Ia, LFA-1 and ICAM-1 inhibited presentation. Our studies also showed that synoviocytes and spleen cells took up and processed PG more rapidly than the cell lines. Cysteine and serine protease-dependent antigen presentation of PG was blocked at 4 degrees C, 18 degrees C and by chloroquine treatment, indicating that presentation required active uptake and processing in an acidic compartment, probably in lysosomes. Also, keratan sulphate-depleted and cyanogen bromide (CNBr) and 2-nitro-5-thiocyanobenzoic acid (NTCB)-cleaved PG elicited stronger T cell responses, as they were more easily processed than the native molecule. Furthermore, CNBr-generated peptides were presented by fixed APC, indicating that core protein fragments of cartilage PG can be presented directly by APC in context with MHC class II molecules.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697908      PMCID: PMC1534264          DOI: 10.1111/j.1365-2249.1995.tb03610.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  A group-specific inhibitor of lysosomal cysteine proteinases selectively inhibits both proteolytic degradation and presentation of the antigen dinitrophenyl-poly-L-lysine by guinea pig accessory cells to T cells.

Authors:  S Buus; O Werdelin
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

2.  Monoclonal antibodies to different protein-related epitopes of human articular cartilage proteoglycans.

Authors:  T T Glant; K Mikecz; A R Poole
Journal:  Biochem J       Date:  1986-02-15       Impact factor: 3.857

3.  The inhibition of macrophage protein turnover by a selective inhibitor of thiol proteinases.

Authors:  E Shaw; R T Dean
Journal:  Biochem J       Date:  1980-02-15       Impact factor: 3.857

4.  Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, and a nonarthritic control population.

Authors:  E E Golds; I B Stephen; J M Esdaile; H Strawczynski; A R Poole
Journal:  Cell Immunol       Date:  1983-11       Impact factor: 4.868

5.  Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes.

Authors:  K Ziegler; E R Unanue
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

6.  Mediators and autopathogenic effector cells in proteoglycan-induced arthritic and clinically asymptomatic BALB/c mice.

Authors:  E I Buzás; K Mikecz; F R Brennan; T T Glant
Journal:  Cell Immunol       Date:  1994-10-15       Impact factor: 4.868

7.  Human interleukin 1 mediates cartilage matrix degradation.

Authors:  T Krakauer; J J Oppenheim; H E Jasin
Journal:  Cell Immunol       Date:  1985-03       Impact factor: 4.868

8.  Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology.

Authors:  T T Glant; K Mikecz; A Arzoumanian; A R Poole
Journal:  Arthritis Rheum       Date:  1987-02

Review 9.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  7 in total

1.  Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice.

Authors:  Ferenc Boldizsar; Katalin Kis-Toth; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Rheum       Date:  2010-10

2.  T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice.

Authors:  K Olasz; F Boldizsar; K Kis-Toth; O Tarjanyi; A Hegyi; W van Eden; T A Rauch; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

3.  Aggrecan: A Target Molecule of Autoimmune Reactions.

Authors:  Edit I Buzás; Katalin Mikecz; Tibor T Glant
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

4.  Antigen-specific B cells present cartilage proteoglycan (aggrecan) to an autoreactive T cell hybridoma derived from a mouse with proteoglycan-induced arthritis.

Authors:  F R Brennan; K Mikecz; E I Buzás; D Ragasa; G Cs-Szabó; G Negroiu; T T Glant
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

Review 5.  Tissue-associated autoantigens in rheumatoid arthritis. Tissue-antigens detected by autoantibodies in synovial fluid and sera of RA patients.

Authors:  P von Landenberg; J Schölmerich
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

Review 6.  Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis.

Authors:  A Hanyecz; K Olasz; O Tarjanyi; P Nemeth; K Mikecz; T T Glant; F Boldizsar
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

Review 7.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.